GRAL
GRAIL, Inc.
There isn't enough reported data to score GRAL yet.
GRAL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
GRAL's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
GRAL PE Valuation
GRAL has no meaningful PE right now: it lost money over the past year.
GRAL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect GRAL's revenue to grow, with its earnings and profitability holding steady.
GRAL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$9.43 | +$2.35 |
| Q2 2026 | -$9.68 | +$3.58 |
| Q1 2026 | -$10.30 | +$50.84 |
| Q4 2025 | -$11.11 | +$53.98 |
| Q3 2025 | -$11.78 | +$50.45 |
| Q2 2025 | -$13.26 | +$73.74 |
| Q1 2025 | -$61.14 | -$18.98 |
| Q4 2024 | -$65.09 | -$23.74 |
GRAL is still losing money, but far less than before: $9.43 per share over the past year, against $87.00 at its worst in mid-2024.
GRAL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.5M | +3.7% |
| Q2 2026 | $44.7M | +26% |
| Q1 2026 | $40.8M | +28% |
| Q4 2025 | $43.6M | +14% |
| Q3 2025 | $36.2M | +26% |
| Q2 2025 | $35.5M | +11% |
| Q1 2025 | $31.8M | +19% |
| Q4 2024 | $38.3M | +26% |
GRAL's revenue has grown year over year every quarter since early 2024: $38M last quarter, up 3.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -385% | -39 points |
| Q2 2026 | -389% | +58 points |
| Q1 2026 | -333% | +150 points |
| Q4 2025 | -285% | +73 points |
| Q3 2025 | -346% | +294 points |
| Q2 2025 | -447% | +4687 points |
| Q1 2025 | -482% | +369 points |
| Q4 2024 | -358% | +284 points |
GRAL's operating margin was −385% last quarter, down 39 points from the same quarter a year ago.
GRAL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$79.5M | -$15.8M |
| Q2 2026 | -$81.2M | -$3.8M |
| Q1 2026 | -$87.5M | +$7.6M |
| Q3 2025 | -$63.6M | +$41M |
| Q1 2025 | -$95.1M | +$114.8M |
| Q3 2024 | -$104.6M | +$56M |
| Q1 2024 | -$209.8M | -$36.3M |
GRAL has burned cash in almost every quarter: −$312M over the past year, against −$341M the year before.
GRAL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8.5% | +3.7M shares |
| 1 year | +29% | +10.7M shares |
| 3 years | +51% | +15.7M shares |
GRAL has 47M diluted shares, up 29% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | $14,000 |
| Q3 2023 | — |
| Q2 2023 | $95,000 |
| Q1 2023 | — |
GRAL Net Leverage
GRAL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
GRAL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.0 | Neutral |
| Stochastic | 63.5 | Neutral |
GRAL's weekly RSI is 60 (neutral) and its Stochastic is 64 (neutral).
GRAL PE vs Healthcare Sector
GRAL has no meaningful PE right now: it lost money over the past year.
GRAL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $130.9 | 7.3% below |
| 20 week MA | $96.6 | 26% above |
| 50 week MA | $81.1 | 50% above |
| 100 week MA | $62.1 | 95% above |
GRAL's trend is up, with a small recent dip: it's below only its 8-week average, and 95% above its 100-week average.
GRAL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $17.2 | $19.6 | +14% |
| 2025 | $19.6 | $91.6 | +367% |
| 2026 YTD | $91.6 | $121.4 | +32% |
GRAL has finished every year since 2024 higher, and it's up 32% so far in 2026.